The Canadian prospective cohort study to understand progression in multiple sclerosis (CanProCo): rationale, aims, and study design
Abstract Background Neurological disability progression occurs across the spectrum of people living with multiple sclerosis (MS). Although there are a handful of disease-modifying treatments approved for use in progressive phenotypes of MS, there are no treatments that substantially modify the cours...
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2021-10-01
|
| Series: | BMC Neurology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12883-021-02447-7 |
| _version_ | 1798035215515385856 |
|---|---|
| author | Jiwon Oh Nathalie Arbour Fabrizio Giuliani Melanie Guenette Shannon Kolind Larry Lynd Ruth Ann Marrie Luanne M. Metz Scott B. Patten Alexandre Prat Alice Schabas Penelope Smyth Roger Tam Anthony Traboulsee V. Wee Yong |
| author_facet | Jiwon Oh Nathalie Arbour Fabrizio Giuliani Melanie Guenette Shannon Kolind Larry Lynd Ruth Ann Marrie Luanne M. Metz Scott B. Patten Alexandre Prat Alice Schabas Penelope Smyth Roger Tam Anthony Traboulsee V. Wee Yong |
| author_sort | Jiwon Oh |
| collection | DOAJ |
| description | Abstract Background Neurological disability progression occurs across the spectrum of people living with multiple sclerosis (MS). Although there are a handful of disease-modifying treatments approved for use in progressive phenotypes of MS, there are no treatments that substantially modify the course of clinical progression in MS. Characterizing the determinants of clinical progression can inform the development of novel therapeutic agents and treatment approaches that target progression in MS, which is one of the greatest unmet needs in clinical practice. Canada, having one of the world’s highest rates of MS and a publicly-funded health care system, represents an optimal country to achieve in-depth analysis of progression. Accordingly, the overarching aim of the Canadian Prospective Cohort Study to Understand Progression in MS (CanProCo) is to evaluate a wide spectrum of factors associated with the clinical onset and rate of disease progression in MS, and to describe how these factors relate to one another to influence progression. Methods CanProCo is a prospective, observational cohort study with investigators specializing in epidemiology, neuroimaging, neuroimmunology, health services research and health economics. CanProCo’s study design was approved by an international review panel, comprised of content experts and key stakeholders. One thousand individuals with radiologically-isolated syndrome, relapsing-remitting MS, and primary-progressive MS within 10–15 years of disease onset will be recruited from 5 academic MS centres in Canada. Participants will undergo detailed clinical evaluation annually over 5 years (including advanced, app-based clinical data collection). In a subset of participants within 5–10 years of disease onset (n = 500), blood, cerebrospinal fluid, and research MRIs will be collected allowing an integrated, in-depth evaluation of factors contributing to progression in MS from multiple perspectives. Factors of interest range from biological measures (e.g. single-cell RNA-sequencing), MRI-based microstructural assessment, participant characteristics (self-reported, performance-based, clinician-assessed, health-system based), and micro and macro-environmental factors. Discussion Halting the progression of MS remains a fundamental need to improve the lives of people living with MS. Achieving this requires leveraging transdisciplinary approaches to better characterize why clinical progression occurs. CanProCo is a pioneering multi-dimensional cohort study aiming to characterize these determinants to inform the development and implementation of efficacious and effective interventions. |
| first_indexed | 2024-04-11T20:55:08Z |
| format | Article |
| id | doaj.art-eb244b7ca06b45aca81b35c146d52676 |
| institution | Directory Open Access Journal |
| issn | 1471-2377 |
| language | English |
| last_indexed | 2024-04-11T20:55:08Z |
| publishDate | 2021-10-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Neurology |
| spelling | doaj.art-eb244b7ca06b45aca81b35c146d526762022-12-22T04:03:44ZengBMCBMC Neurology1471-23772021-10-0121111910.1186/s12883-021-02447-7The Canadian prospective cohort study to understand progression in multiple sclerosis (CanProCo): rationale, aims, and study designJiwon Oh0Nathalie Arbour1Fabrizio Giuliani2Melanie Guenette3Shannon Kolind4Larry Lynd5Ruth Ann Marrie6Luanne M. Metz7Scott B. Patten8Alexandre Prat9Alice Schabas10Penelope Smyth11Roger Tam12Anthony Traboulsee13V. Wee Yong14Division of Neurology, St. Michael’s Hospital, University of TorontoDepartment of Neurosciences, Université de Montréal and Centre hospitalier de l’Université de MontréalDivision of Neurology, Department of Medicine and Neuroscience and Mental Health Institute, University of AlbertaDivision of Neurology, St. Michael’s Hospital, University of TorontoDepartment of Medicine, Division of Neurology, University of British ColumbiaFaculty of Pharmaceutical Sciences, University of British ColumbiaDepartments of Internal Medicine and Community Health Sciences, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of ManitobaDepartment of Clinical Neurosciences, University of Calgary Foothills HospitalDepartment of Community Health Sciences, University of CalgaryDepartment of Neurosciences, Université de Montréal and Centre hospitalier de l’Université de MontréalDepartment of Medicine, Division of Neurology, University of British ColumbiaDivision of Neurology, Department of Medicine and Neuroscience and Mental Health Institute, University of AlbertaDepartment of Radiology, University of British ColumbiaDepartment of Medicine, Division of Neurology, University of British ColumbiaDepartment of Clinical Neurosciences and the Hotchkiss Brain Institute, University of CalgaryAbstract Background Neurological disability progression occurs across the spectrum of people living with multiple sclerosis (MS). Although there are a handful of disease-modifying treatments approved for use in progressive phenotypes of MS, there are no treatments that substantially modify the course of clinical progression in MS. Characterizing the determinants of clinical progression can inform the development of novel therapeutic agents and treatment approaches that target progression in MS, which is one of the greatest unmet needs in clinical practice. Canada, having one of the world’s highest rates of MS and a publicly-funded health care system, represents an optimal country to achieve in-depth analysis of progression. Accordingly, the overarching aim of the Canadian Prospective Cohort Study to Understand Progression in MS (CanProCo) is to evaluate a wide spectrum of factors associated with the clinical onset and rate of disease progression in MS, and to describe how these factors relate to one another to influence progression. Methods CanProCo is a prospective, observational cohort study with investigators specializing in epidemiology, neuroimaging, neuroimmunology, health services research and health economics. CanProCo’s study design was approved by an international review panel, comprised of content experts and key stakeholders. One thousand individuals with radiologically-isolated syndrome, relapsing-remitting MS, and primary-progressive MS within 10–15 years of disease onset will be recruited from 5 academic MS centres in Canada. Participants will undergo detailed clinical evaluation annually over 5 years (including advanced, app-based clinical data collection). In a subset of participants within 5–10 years of disease onset (n = 500), blood, cerebrospinal fluid, and research MRIs will be collected allowing an integrated, in-depth evaluation of factors contributing to progression in MS from multiple perspectives. Factors of interest range from biological measures (e.g. single-cell RNA-sequencing), MRI-based microstructural assessment, participant characteristics (self-reported, performance-based, clinician-assessed, health-system based), and micro and macro-environmental factors. Discussion Halting the progression of MS remains a fundamental need to improve the lives of people living with MS. Achieving this requires leveraging transdisciplinary approaches to better characterize why clinical progression occurs. CanProCo is a pioneering multi-dimensional cohort study aiming to characterize these determinants to inform the development and implementation of efficacious and effective interventions.https://doi.org/10.1186/s12883-021-02447-7Multiple sclerosisCohortProspectiveProgressionProgressive MSEpidemiology |
| spellingShingle | Jiwon Oh Nathalie Arbour Fabrizio Giuliani Melanie Guenette Shannon Kolind Larry Lynd Ruth Ann Marrie Luanne M. Metz Scott B. Patten Alexandre Prat Alice Schabas Penelope Smyth Roger Tam Anthony Traboulsee V. Wee Yong The Canadian prospective cohort study to understand progression in multiple sclerosis (CanProCo): rationale, aims, and study design BMC Neurology Multiple sclerosis Cohort Prospective Progression Progressive MS Epidemiology |
| title | The Canadian prospective cohort study to understand progression in multiple sclerosis (CanProCo): rationale, aims, and study design |
| title_full | The Canadian prospective cohort study to understand progression in multiple sclerosis (CanProCo): rationale, aims, and study design |
| title_fullStr | The Canadian prospective cohort study to understand progression in multiple sclerosis (CanProCo): rationale, aims, and study design |
| title_full_unstemmed | The Canadian prospective cohort study to understand progression in multiple sclerosis (CanProCo): rationale, aims, and study design |
| title_short | The Canadian prospective cohort study to understand progression in multiple sclerosis (CanProCo): rationale, aims, and study design |
| title_sort | canadian prospective cohort study to understand progression in multiple sclerosis canproco rationale aims and study design |
| topic | Multiple sclerosis Cohort Prospective Progression Progressive MS Epidemiology |
| url | https://doi.org/10.1186/s12883-021-02447-7 |
| work_keys_str_mv | AT jiwonoh thecanadianprospectivecohortstudytounderstandprogressioninmultiplesclerosiscanprocorationaleaimsandstudydesign AT nathaliearbour thecanadianprospectivecohortstudytounderstandprogressioninmultiplesclerosiscanprocorationaleaimsandstudydesign AT fabriziogiuliani thecanadianprospectivecohortstudytounderstandprogressioninmultiplesclerosiscanprocorationaleaimsandstudydesign AT melanieguenette thecanadianprospectivecohortstudytounderstandprogressioninmultiplesclerosiscanprocorationaleaimsandstudydesign AT shannonkolind thecanadianprospectivecohortstudytounderstandprogressioninmultiplesclerosiscanprocorationaleaimsandstudydesign AT larrylynd thecanadianprospectivecohortstudytounderstandprogressioninmultiplesclerosiscanprocorationaleaimsandstudydesign AT ruthannmarrie thecanadianprospectivecohortstudytounderstandprogressioninmultiplesclerosiscanprocorationaleaimsandstudydesign AT luannemmetz thecanadianprospectivecohortstudytounderstandprogressioninmultiplesclerosiscanprocorationaleaimsandstudydesign AT scottbpatten thecanadianprospectivecohortstudytounderstandprogressioninmultiplesclerosiscanprocorationaleaimsandstudydesign AT alexandreprat thecanadianprospectivecohortstudytounderstandprogressioninmultiplesclerosiscanprocorationaleaimsandstudydesign AT aliceschabas thecanadianprospectivecohortstudytounderstandprogressioninmultiplesclerosiscanprocorationaleaimsandstudydesign AT penelopesmyth thecanadianprospectivecohortstudytounderstandprogressioninmultiplesclerosiscanprocorationaleaimsandstudydesign AT rogertam thecanadianprospectivecohortstudytounderstandprogressioninmultiplesclerosiscanprocorationaleaimsandstudydesign AT anthonytraboulsee thecanadianprospectivecohortstudytounderstandprogressioninmultiplesclerosiscanprocorationaleaimsandstudydesign AT vweeyong thecanadianprospectivecohortstudytounderstandprogressioninmultiplesclerosiscanprocorationaleaimsandstudydesign AT jiwonoh canadianprospectivecohortstudytounderstandprogressioninmultiplesclerosiscanprocorationaleaimsandstudydesign AT nathaliearbour canadianprospectivecohortstudytounderstandprogressioninmultiplesclerosiscanprocorationaleaimsandstudydesign AT fabriziogiuliani canadianprospectivecohortstudytounderstandprogressioninmultiplesclerosiscanprocorationaleaimsandstudydesign AT melanieguenette canadianprospectivecohortstudytounderstandprogressioninmultiplesclerosiscanprocorationaleaimsandstudydesign AT shannonkolind canadianprospectivecohortstudytounderstandprogressioninmultiplesclerosiscanprocorationaleaimsandstudydesign AT larrylynd canadianprospectivecohortstudytounderstandprogressioninmultiplesclerosiscanprocorationaleaimsandstudydesign AT ruthannmarrie canadianprospectivecohortstudytounderstandprogressioninmultiplesclerosiscanprocorationaleaimsandstudydesign AT luannemmetz canadianprospectivecohortstudytounderstandprogressioninmultiplesclerosiscanprocorationaleaimsandstudydesign AT scottbpatten canadianprospectivecohortstudytounderstandprogressioninmultiplesclerosiscanprocorationaleaimsandstudydesign AT alexandreprat canadianprospectivecohortstudytounderstandprogressioninmultiplesclerosiscanprocorationaleaimsandstudydesign AT aliceschabas canadianprospectivecohortstudytounderstandprogressioninmultiplesclerosiscanprocorationaleaimsandstudydesign AT penelopesmyth canadianprospectivecohortstudytounderstandprogressioninmultiplesclerosiscanprocorationaleaimsandstudydesign AT rogertam canadianprospectivecohortstudytounderstandprogressioninmultiplesclerosiscanprocorationaleaimsandstudydesign AT anthonytraboulsee canadianprospectivecohortstudytounderstandprogressioninmultiplesclerosiscanprocorationaleaimsandstudydesign AT vweeyong canadianprospectivecohortstudytounderstandprogressioninmultiplesclerosiscanprocorationaleaimsandstudydesign |